PN and RFA offer similar survival for cT1a RCC tumors ≤2 cm, but PN is superior for larger tumors. RFA may be considered for elderly patients with comorbidities, especially for tumors ≤2 cm. PN ...
Investigators are exploring whether combinational therapies can improve survival for patients with renal cell carcinoma or muscle-invasive bladder cancer.
Moderate to advanced chronic kidney disease is an underappreciated burden of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC) treated with surgery, which also includes frequent disease ...
Non-clear cell renal cell carcinoma in the immune checkpoint era: A retrospective study on survival and treatment approaches. Multivariable Cox regression models demonstrating variables associated ...
First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results